Postprogression Treatment
In total, 55 patients (68.8%) in the gefitinib plus chemotherapy group and 64 patients (79.0%) in the gefitinib group received at least 1 subsequent therapy after progression; details of the postprogression therapy are listed in eTable 4 in 